{{Drugbox
| verifiedrevid = 460780226
| IUPAC_name = 4-[(2''S'')-2-(3,5-Dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
| image = Dexrazoxane.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|dexrazoxane-hydrochloride}}
| MedlinePlus = a609010
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =
<!--Identifiers-->
| IUPHAR_ligand = 7330
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 24584-09-6
| ATC_prefix = V03
| ATC_suffix = AF02
| ATC_supplemental =  
| PubChem = 71384
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00380
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 64479
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 048L81261F
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03730
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50223
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1738
<!--Chemical data-->
| C=11 | H=16 | N=4 | O=4
| molecular_weight = 268.269 g/mol
| smiles = O=C2NC(=O)CN(C[C@@H](N1CC(=O)NC(=O)C1)C)C2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BMKDZUISNHGIBY-ZETCQYMHSA-N
}}
'''Dexrazoxane hydrochloride''' ('''Zinecard''' by [[Pfizer]] in USA and Canada; '''Cardioxane''' by Clinigen Group for EU and other countries) is a cardioprotective agent. It was discovered by [[Kurt Hellmann]] in 1972. Dexrazoxane is a sterile, pyrogen-free lyophilizate intended for intravenous administration. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH.<ref>http://www.rxlist.com/zinecard-drug.htm</ref>

==Uses==
Dexrazoxane has been used to protect the [[heart]] against the [[cardiotoxic]] side effects of chemotherapeutic drugs such as [[anthracycline]]s,<ref name="pmid15247354">{{cite journal |doi=10.1056/NEJMoa035153 |title=The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia |year=2004 |last1=Lipshultz |first1=Steven E. |last2=Rifai |first2=Nader |last3=Dalton |first3=Virginia M. |last4=Levy |first4=Donna E. |last5=Silverman |first5=Lewis B. |last6=Lipsitz |first6=Stuart R. |last7=Colan |first7=Steven D. |last8=Asselin |first8=Barbara L. |last9=Barr |first9=Ronald D. |last10=Clavell |first10=Luis A. |last11=Hurwitz |first11=Craig A. |last12=Moghrabi |first12=Albert |last13=Samson |first13=Yvan |last14=Schorin |first14=Marshall A. |last15=Gelber |first15=Richard D. |last16=Sallan |first16=Stephen E. |journal=New England Journal of Medicine |volume=351 |issue=2 |pages=145–53 |pmid=15247354|display-authors=8 }}</ref> such as [[daunorubicin]] or [[doxorubicin]] or other chemotherapeutic agents.<ref name="pmid18040065">{{cite journal |doi=10.3181/0705-RM-138 |title=Effects of Dexrazoxane and Amifostine on Evolution of Doxorubicin Cardiomyopathy in Vivo |year=2007 |last1=Bjelogrlic |first1=Snezana K. |last2=Radic |first2=Jelena |last3=Radulovic |first3=Sinisa |last4=Jokanovic |first4=Milan |last5=Jovic |first5=Viktor |journal=Experimental Biology and Medicine |volume=232 |issue=11 |pages=1414–24 |pmid=18040065}}</ref> However, in July 2011 the US Food and Drug Administration released a statement restricting use only in adult patients with cancer who have received > 300&nbsp;mg/m2 doxorubicin (an anthracycline) or > 540&nbsp;mg/m2 epirubicin (another chemotherapeutic agent) and general approval for use for cardioprotection.<ref>Tebbi CK, et al. J Clin Oncol 2007; 25: 493–500</ref><ref>Salzer WL, et al. Leukemia 2010; 24: 355–70</ref> That showed a possibly higher rate of secondary malignancies and acute myelogenous leukemia in pediatric patients treated for different cancers with both dexrazoxane and other chemotherapeutic agents that are associated with secondary malignancies.<ref>{{cite web|url= http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm|title= FDA Statement on Dexrazoxane}}</ref>

The United States [[Food and Drug Administration]] has also approved a dexrazoxane hydrochloride drug, brand names Totect and Savene (approved in the EU) marketed by Clinigen Group, for use as a treatment of [[extravasation]] resulting from IV [[anthracycline]] [[chemotherapy]].<ref>[http://www.fda.gov/cder/foi/label/2007/022025lbl.pdf Totect label on FDA's website]</ref><ref name="pmid18448560">{{cite journal |doi=10.1634/theoncologist.2007-0247 |title=Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemotherapy |year=2008 |last1=Kane |first1=Robert C. |last2=McGuinn |first2=W. David |last3=Dagher |first3=Ramzi |last4=Justice |first4=Robert |last5=Pazdur |first5=Richard |journal=The Oncologist |volume=13 |issue=4 |pages=445–50 |pmid=18448560}}</ref> Extravasation is an [[adverse event]] in which chemotherapies containing anthracylines leak out of the blood vessel and [[necrotize]] the surrounding tissue.

==Mechanism==
As a derivative of [[EDTA]], dexrazoxane [[chelate]]s [[iron]] and thus reduces the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals.<ref>{{cite journal |doi=10.1586/14779072.6.10.1311 |title=Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity |year=2008 |last1=Jones |first1=Robin L. |journal=Expert Review of Cardiovascular Therapy |volume=6 |issue=10 |pages=1311–7 |pmid=19018683}}</ref> The exact chelation mechanism is unknown, but it has been postulated that dexrazoxane can be converted into ring-opened form intracellularly and interfere with iron-mediated free radical generation that is in part thought to be responsible for anthryacycline induced cadiomyopathy.<ref>http://labeling.pfizer.com/ShowLabeling.aspx?id=514</ref> It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs.<ref>{{cite journal |doi=10.1006/expr.1998.4371 |title=''Plasmodium falciparum'' and ''Plasmodium yoelii'': Effect of the Iron Chelation Prodrug Dexrazoxane on ''in Vitro'' Cultures |year=1999 |last1=Loyevsky |first1=Mark |journal=Experimental Parasitology |volume=91 |issue=2 |pages=105–14 |pmid=9990337 |last2=Sacci |first2=John B. |last3=Boehme |first3=Patricia |last4=Weglicki |first4=William |last5=John |first5=Christy |last6=Gordeuk |first6=Victor R.}}</ref>

==References==
{{reflist|2}}

{{Detoxifying agents for antineoplastic treatment}}
{{Chelating agents}}

[[Category:Chelating agents]]
[[Category:Chelating agents used as drugs]]
[[Category:Chemotherapeutic adjuvants]]
[[Category:Imides]]
[[Category:Enantiopure drugs]]
[[Category:Diketopiperazines]]